Gyre Therapeutics

Gyre Therapeutics, founded in 2002, is a biopharmaceutical company headquartered in San Diego, California, and trades under the ticker NASDAQ: GYRE. The firm specializes in the development and commercialization of advanced therapies targeting liver fibrosis and various metabolic and pulmonary diseases. By focusing on high-unmet-need conditions, the company maintains a robust clinical pipeline that includes treatments for interstitial lung disease, chronic obstructive pulmonary disease, and pulmonary arterial hypertension.

The organization operates with 500-1,000 employees dedicated to advancing its clinical-stage assets. Meet Gyre Therapeutics's team to understand the leadership driving these complex pharmaceutical initiatives. The company’s lead program, Hydronidone, is currently undergoing rigorous clinical evaluation in both the United States and China, representing a significant milestone in their therapeutic development strategy. This focus on global clinical trials underscores their commitment to addressing serious organ-related diseases through innovative biopharmaceutical research and development.

Financially, Gyre Therapeutics demonstrates strong market positioning with annual revenue of $109.8M. The company continues to secure capital, including a recent $23.0M stock issuance in May 2025, to support its ongoing research efforts. Explore financial highlights to review detailed metrics and funding history. Operating within a competitive landscape that includes firms like Madrigal Pharmaceuticals and Akebia Therapeutics, the company leverages its specialized focus to maintain a distinct market presence in the healthcare sector.